Med by Cell Press

New in Med by Cell Press: In metastatic pancreatic cancer, not all patients benefit from first-line chemotherapy FOLFIRINOX. Those without a KRAS mutation (KRAS wild type) had significantly longer median overall survival compared to those with the mutation (17.7 months vs. 7.8 months) https://lnkd.in/eySZQAdS The study used whole-genome sequencing on pre-treatment biopsies. KRAS wild-type tumors exhibited different biological characteristics and did not conform to existing RNA-based prognostic classifiers. Evaluating KRAS status, alongside genomic targets for therapy, may enhance prognostic modeling and help identify patients more suitable for alternative treatments rather than FOLFIRINOX. Marjolein Lansbergen ∙ Mark Dings ∙ Jan Koster ∙ Mariette Labots ∙ Emile D. Kerver ∙ Anouk Jochems ∙ Marjolein Y.V. Homs ∙ Judith de Vos-Geelen ∙ Mathijs P. Hendriks ∙ Michael Tanck ∙ Johanna W. Wilmink ∙ Hanneke van Laarhoven ∙ Maarten Bijlsma Amsterdam UMC, Amsterdam UMC - Cancer Center Amsterdam OLVG Haaglanden Medisch Centrum (HMC) Erasmus MC Cancer Institute Maastricht University Medical Center Northwest Clinics #PancreaticCancer #Metastatic #PDAC #FOLFIRINOX #KRASMutation #PrognosticMarkers #WholeGenomeSequencing

Online Now: KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer http://dlvr.it/THw8Y1

Online Now: HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study http://dlvr.it/THjwJg

First-in-human phase 1 study evaluated HMPL-306, an oral dual inhibitor targeting mutated IDH1/2, for patients with relapsed/refractory AML https://lnkd.in/ee7ZyU_z The study demonstrated a satisfactory safety profile, with no dose-limiting toxicities and a recommended phase 2 dose of 250 mg for cycle 1 and 150 mg for subsequent cycles. Preliminary efficacy results were encouraging, showing a complete remission rate of 34.6% in mIDH1 and 36.4% in mIDH2 subgroups, along with a median overall survival of approximately 13 months for both groups. These findings support further development in a larger phase 3 randomized trial. #AcuteMyeloidLeukemia #AML #HMPL306 #Immunotherapy #ClinicalTrial #PrecisionOncology

A new clinical trial in Med by Cell Press investigated the efficacy of combining toripalimab, a humanized anti-PD1 antibody, with chemotherapy in patients with initially unresectable stage IIIA–IIIB NSCLC https://lnkd.in/ezrqh3uB Out of 40 patients, 72.5% experienced significant tumor shrinkage, enabling surgical intervention, with all achieving complete tumor removal (100% R0 resection rate). The treatment was well tolerated, with manageable side effects and no major safety issues. These results suggest that pre-operative toripalimab combined with chemotherapy may be an effective approach to convert unresectable NSCLC into a resectable form, providing a promising new treatment option for this challenging condition. #LungCancer #NSCLC #Toripalimab #Immunotherapy #Chemotherapy #ClinicalTrial #TumorShrinkage

Online Now: Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial http://dlvr.it/THhvwp

Have you read the latest issue of Med by Cell Press? It's online now: https://hubs.li/Q034mc4R0 On the cover: Immunotherapy has revolutionized the standards of care for individuals with cancer, yet not all patients obtain long-lasting benefit from these therapies. This month, we feature a special issue covering the latest developments in cancer immunotherapeutics, ranging from cell-based therapies to vaccines and tumor-targeting bacteria. Through a series of Q&As, reviews and opinion pieces, we seek to highlight some existing challenges in this field as well as potential breakthroughs that may improve efficacy and deliver on the clinical promise of immunotherapy. Cover image: Isaac Lane Koval/Corbis/VCG via Getty Images.

Explore our special issue on the latest developments in cancer immunotherapeutics: https://lnkd.in/e3kFp_2C Immunotherapy has revolutionized the standards of care for individuals with cancer, yet not all patients obtain long-lasting benefit from these therapies. This month, we feature a special issue covering the latest developments in cancer immunotherapeutics, ranging from cell-based therapies to vaccines and tumor-targeting bacteria. Through a series of Q&As, reviews and opinion pieces, we seek to highlight some existing challenges in this field as well as potential breakthroughs that may improve efficacy and deliver on the clinical promise of immunotherapy. Featuring special pieces from: Shimon Slavin Wei Tao Lin Shen Peyraud, Italiano, & colleagues Min, Forbes, & colleagues Adashek, Munoz, & Kurzrock #Immunotherapy #CancerResearch #CellBasedTherapies #CancerVaccines #TumorTargeting #ClinicalTrials

Online Now: IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial http://dlvr.it/THRFT2

A phase 2 randomized controlled trial assessed the efficacy and safety of combining CTLA-4 blockade (IBI310) with PD-1/PD-L1 blockade (sintilimab) in patients with recurrent/metastatic cervical cancer (R/M CC) https://lnkd.in/e22dC_Bb The study found no significant improvement in objective response rate, progression-free survival, or overall survival with the combination therapy; however, it did increase the incidence of grade ≥3 treatment-related adverse events. These results underscore the need for further investigation into the role of CTLA-4 in the cervical cancer microenvironment and the development of safer combination therapies. #CervicalCancer #Immunotherapy #CTLA4 #PD1 #PDL1 #ClinicalTrial #CombinationTherapy